We are an R&D-driven company, focusing on the development of iPS cell-based regenerative medicine and the application of iPS cell technologies.

In 2015, the Center for iPS Cell Research and Application (CiRA), Kyoto University and Takeda Pharmaceutical Company Limited launched the joint research program T-CiRA to accelerate the research and advancement of iPS cell technologies as well as its application in regenerative medicine and drug development. In 2021, Orizuru Therapeutics Inc. was established for the purpose of transferring some of their outcomes into clinical practices as sustainable business.

Our portfolio is initially focused on two potential therapies researched under the T-CiRA program. One is with iPS cell-derived cardiomyocytes led by Project Leader Yoshinori Yoshida (Associate Professor at CiRA) and the other is with iPS cell-derived pancreatic islet cells led by Project Leader Taro Toyoda (Junior Associate Professor at CiRA). We will continue to seek other potential therapy where iPS cell technology may play a critical role. Another business scope is to support any drug discovery research activities and to build an iPS cell research platform based on our advancing iPS cell technologies.

Even though we have just started, we are comprised of over 50 staff who are either best-in-class researchers or with in-depth expertise as technicians in the latest iPS cell technologies. We have a mind in young, open, and free, yet our heart is “to help society and patients per iPS cell technologies come from Japan.” This is the origin of our company's name, Orizuru.

We inherit the scientific technologies of CiRA and Takeda, and will build new cultures on top of these here at Shonan iPark campus, Kanagawa, Japan. By providing regenerative medicines, we will contribute to the future for medical practice, our people, and our society.